Cao Hao, general manager of Silicon Gene Biotech, praised Shanghai's Hongqiao International Central Business District as a major hub for tech innovation with a supportive industrial and talent ecosystem.
Under his leadership, the firm has achieved groundbreaking progress in 30-minute rapid blood screening technology for Alzheimer's disease.
A seasoned neuroscience researcher and recipient of Shanghai's Oriental Elite Program, Cao emphasized that Hongqiao's unique advantages empower both enterprises and talent to thrive.
The biomedical industry cluster enables efficient cooperation among nearby enterprises, hospitals and research institutes, facilitating academic exchanges, clinical collaboration and resource sharing while reducing the need for cross-region travel.
He spoke highly of Hongqiao's open and collaborative innovation atmosphere, comprehensive shared lab platforms, regular industry seminars and one-stop professional services covering medical registration, intellectual property and investment. Supported by Hongqiao's strong transportation and exhibition resources, the team can easily connect with nationwide medical institutions and partners.
Backed by Hongqiao's tailored talent policies and sound industrial ecosystem, Silicon Gene Biotech has overcome core technical bottlenecks and completed thousands of valid clinical tests. Cao noted that Hongqiao's full-chain support lets talent focus on core research priorities, driving continuous innovation in neuro-diagnostic technologies.
